Country: Awstralja
Lingwa: Ingliż
Sors: Department of Health (Therapeutic Goods Administration)
oxycodone hydrochloride, Quantity: 10 mg
Arrotex Pharmaceuticals Pty Ltd
oxycodone hydrochloride
Tablet, modified release
Excipient Ingredients: colloidal anhydrous silica; macrogol 8000; titanium dioxide; magnesium stearate; hyprolose; lactose; ethylcellulose; hypromellose
Oral
60, 20, 28
(S8) Controlled Drug
GENRX OXYCODONE MR modified release tablets are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long-term treatment. GENRX OXYCODONE MR is not indicated for the use in chronic non-cancer pain other than in exceptional circumstances. GENRX OXYCODONE MR is not indicated as an as-needed (PRN) analgesia.
Visual Identification: White, round, biconvex film-coated tablet, engraved 'APO' on one side, 'OCD' over '10' on the other side.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Licence status A
2014-11-21